Skip to content

Genetic Aortic Diseases and Cardiovascular Complications. An Observational Survey of Risk Factors.

Genetic Aortic Diseases and Cardiovascular Complications. An Observational Survey of Risk Factors.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07391293
Acronym
PROM-1
Enrollment
208
Registered
2026-02-05
Start date
2025-05-06
Completion date
2027-05-01
Last updated
2026-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic Aortic Aneurysm (TAA)

Keywords

risk stratification, quality of life, rare disease, survey

Brief summary

The aim of this observational study is to define the behavioural and cardiovascular risk factor profiles of patients with genetic aortopathies. The main questions it aims to answer are: * How do the interconnections between lifestyle, stress, psychological condition, perception of illness, and state of health influence each other in this population? * Beyond traditional risk factors, additional emerging factors should be considered, including pregnancy-related complications, sedentary lifestyle, early menopause and depression. The interplay between eating disorders, lifestyle factors and autoimmune or inflammatory bowel diseases remains poorly understood.

Detailed description

Thoracic aortic aneurysms (TAA) present peculiar symptoms as well as high mortality due to complications related to dilatation and dissection of the ascending aorta and great arteries. The presence or absence of extra-aortic features determines whether TAADs are syndromic, associated with diseases affecting other systems and organs, or non-syndromic, with manifestations limited to the aorta. Life expectancy of patients withTAA has improved markedly in the last decades, but still remains lower than that of the general population.

Interventions

OTHERJourney to diagnosis

Questions relating to the course and experience/history of the disease from the onset of symptoms to confirmation of diagnosis; accessibility to referral facilities for treatment and follow-up.

OTHERQuality of life, functional health and well-being

Qestionnaires

OTHERAwareness and self-esteem, acceptance of the condition

questionnaire related to the quality of life and self-care

OTHERpsychological and physical well-being

questionnaire to describe psychological and physical well-being.

Sponsors

IRCCS Policlinico S. Donato
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
14 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* signed onformed consent * Ability to speak, read and write in Italian

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Journey to diagnosis15 monthsThe mean, median, standard deviation and interquartile range will be used for continuous variables, whereas frequency and percentage will be applied for nominal and categorical variables. The Shapiro-Wilks test will be used to assess the Gaussian distributions.
Quality of life, functional health and well-being15 monthsThe mean, median, standard deviation and interquartile range will be used for continuous variables, whereas frequency and percentage will be applied for nominal and categorical variables. The Shapiro-Wilks test will be used to assess the Gaussian distributions.
Awareness and self-esteem, acceptance of the condition15 monthsThe mean, median, standard deviation and interquartile range will be used for continuous variables, whereas frequency and percentage will be applied for nominal and categorical variables. The Shapiro-Wilks test will be used to assess the Gaussian distributions.
psychological and physical well-being15 monthsThe mean, median, standard deviation and interquartile range will be used for continuous variables, whereas frequency and percentage will be applied for nominal and categorical variables. The Shapiro-Wilks test will be used to assess the Gaussian distributions.

Countries

Italy

Contacts

CONTACTAlessandro Pini, MD
alessandro.pini@grupposandonato.it+390252774705

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026